Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORC | P51449 | 15/20 | 0.37 |
| ▸ | JAK2 | O60674 | 1/20 | 0.35 |
| ▸ | JAK1 | P23458 | 1/20 | 0.35 |
| ▸ | JAK3 | P52333 | 1/20 | 0.35 |
| ▸ | RORB | Q92753 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20533564 | 0.85 | GBA1 (0.36) | — | |
| SCHEMBL20533887 | 0.83 | PI4KB (0.47) | KDM4EALDH1A1LMNATSHRSMN1; SMN2 | |
| SCHEMBL20533697 | 0.83 | PI4KB (0.38) | RORCKDM4EALDH1A1SMN1; SMN2HSD17B10 | |
| SCHEMBL20533932 | 0.83 | DPP4 (0.36) | RORCALDH1A1SMN1; SMN2HSD17B10 | |
| SCHEMBL20533930 | 0.82 | SMN1; SMN2 (0.39) | JAK2JAK3KDM4EALDH1A1LMNA | |
| SCHEMBL20533924 | 0.81 | PI4KB (0.45) | ALDH1A1LMNATSHRSMN1; SMN2HSD17B10 | |
| SCHEMBL20533961 | 0.79 | GBA1 (0.37) | RAB9A | |
| SCHEMBL20534228 | 0.79 | GBA1 (0.35) | KDM4EALDH1A1LMNARAB9ASMN1; SMN2 | |
| SCHEMBL20533580 | 0.78 | GBA1 (0.34) | ALDH1A1TSHRRAB9AHSD17B10 | |
| SCHEMBL20533917 | 0.71 | APOBEC3A (0.39) | JAK2KDM4EALDH1A1LMNATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180298009-A1 | Fused Pyrazole Derivatives As Kinase Inhibitors | UCB BIOPHARMA SPRL (BE) | 2018-10-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180298009-A1 | Fused Pyrazole Derivatives As Kinase Inhibitors | PI4KA, PI4K2B, PI4KB | RORC 741/4885JAK2 416/4885JAK1 79/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.